Strong Analytical Validation Data Further Supports Use of DCISionRT® to Guide Shared Decision-Making for DCIS Therapeutic Management

DCISionRT Validated to Have ≥ 95% Sensitivity, Specificity and Accuracy/Reproducibility LAGUNA HILLS, Calif., May 23, 2023 /PRNewswire/ — Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced that a paper…